Model-Based Designs for Identification of Optimal Biological Dose

Haitao Pan () and Ying Yuan ()
Additional contact information
Haitao Pan: St. Jude Children’s Research Hospital, Department of Biostatistics
Ying Yuan: The University of Texas MD Anderson Cancer Center, Department of Biostatistics

Chapter Chapter 4 in Bayesian Adaptive Design for Immunotherapy and Targeted Therapy, 2023, pp 53-70 from Springer

Abstract: Abstract This chapter presents several model-based phase I/II designs, including the EffTox design (Thall & Cook, 2004), the logistic model-based design (Zang et al., 2014), a Bayesian phase I/II design for immunotherapy (Liu et al., 2018), and an isotonic design (Zang et al., 2014). These designs assume a dose-toxicity and dose-efficacy model, and continuously update the estimate of the model in a way similar to the continual reassessment method (CRM). The model estimate is then used to guide dose escalation/de-escalation. Herein, the software of these designs is introduced.

Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-981-19-8176-0_4

Ordering information: This item can be ordered from
http://www.springer.com/9789811981760

DOI: 10.1007/978-981-19-8176-0_4

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().